comparemela.com
Home
Live Updates
T Ornbv Fi0009014377 - Breaking News
Pages:
Latest Breaking News On - T ornbv fi0009014377 - Page 1 : comparemela.com
Orion Group Financial Statement documents 2021, Corporate Governance Statement and Remuneration Report published
ORION CORPORATION STOCK EXCHANGE RELEASE / ANNUAL FINANCIAL REPORT 1 MARCH 2022 at 9.30 EET Orion. | March 1, 2022
Eteläuomen läi
Tuukka hirvonen
Olli huotari
Terhi ormio
Orion group financial statement
Eu press
Orion corporation
Group financial statement
Corporate governance statement
Remuneration report
Financial statement
Financial statements
European single electronic format
Public accountants
Finnish accounting act
Companies act
Darolutamide plus androgen deprivation therapy and docetaxel significantly increases overall survival in patients with metastatic hormone-sensitive prostate cancer
ORION CORPORATION PRESS RELEASE17 FEBRUARY 2022 at 23.32. | February 17, 2022
Eteläuomen läi
Tuukka hirvonen
Eu press
Orion corporation
Investor relations
Cancer statistics
Mortality worldwide
Orion oyj stock exchange
Press release
T ornbv fi0009014377
ARASENS trial with darolutamide in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer
ORION CORPORATION STOCK EXCHANGE RELEASE / INSIDE INFORMATION3 DECEMBER 2021 at 8.30. | December 3, 2021
Eteläuomen läi
Uusimaa region
Tuukka hirvonen
Olli huotari
Timo lappalainen
European union
Orion corporation
Senior vice president
Investor relations
Cancer statistics
Mortality worldwide
Cancer journal
Orion oyj stock exchange
Press release
T ornbv fi0009014377
vimarsana © 2020. All Rights Reserved.